Raissa Reimann, Breno Barreto, Filippo Romano, Jade Medeiros, Bruna C. Camargo, Josiel N. da Silva, Ana Luiza B. Soares, Mateus F. de Souza, Jamile M. Macedo, Anderson M. Kayano, Juliana P. Zuliani, Ana N. de Oliveira, Saulo L. da Silva, Rafaela Diniz-Sousa and Andreimar M. Soares* Pages 1 - 28 ( 28 )
The pursuit of novel treatment alternatives to address the accumulated resistance to antimicrobials over the years has prompted the scientific community to explore biodiversity, particularly animal venom, as a potential source of new antimicrobial drugs. Snake venoms, with their complex mixtures of components, are particularly promising targets for investigation in this regard. The search for novel molecules exhibiting antimicrobial activity against multidrug-resistant strains is of paramount importance for public health and numerous research groups worldwide. High expectations within the healthcare field are supported by the scientific literature, which highlights the potential development of innovative drugs through in vivo and in vitro application, depending on dose titration. Snake venoms and their molecules and peptides offer exponential possibilities for biotechnological applications as antimicrobial agents. However, many uncertainties and unexplored avenues remain, presenting opportunities for discoveries and research.
Biotechnology, snake venom, Bothrops, antimicrobial activity, biomedical applications.